DYN
HEALTHCAREDyne Therapeutics Inc
$18.84+1.37 (+7.84%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving DYN Today?
No stock-specific AI insight has been generated for DYN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.06$25.00
$18.84
Fundamentals
Market Cap$2.9B
P/E Ratio—
EPS$-3.47
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume1.7M
Avg Volume (10D)—
Shares Outstanding165.2M
DYN News
20 articles- Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual MeetingYahoo Finance·Apr 27, 2026
- Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 23, 2026
- Could Dyne Therapeutics’ (DYN) AMCP Spotlight Reveal How New FDA Leadership May Shape Its Pipeline?Yahoo Finance·Apr 15, 2026
- Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular MedicinesYahoo Finance·Apr 1, 2026
- Clearbridge Small Cap Growth Strategy Added Dyne Therapeutics (DYN) in Q4Yahoo Finance·Mar 27, 2026
- This Biotech Was Quietly Bought Before a $58 Per Share TakeoutMotley Fool·Mar 21, 2026
- Dyne Therapeutics Targets 2026 “Breakout Year” With DMD BLA Plans and DM1 Milestones at Stifel ConferenceMarketbeat·Mar 19, 2026
- Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And DataYahoo Finance·Mar 14, 2026
- Dyne Therapeutics (DYN) Shares Key Details For Pivotal. DrugsYahoo Finance·Mar 13, 2026
- Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target UpgradeYahoo Finance·Mar 11, 2026
- Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)Yahoo Finance·Mar 8, 2026
- Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)Yahoo Finance·Mar 8, 2026
- A Look At Dyne Therapeutics (DYN) Valuation After Q4 2025 Earnings Beat And Ongoing Clinical ProgressYahoo Finance·Mar 6, 2026
- Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC FilingMotley Fool·Mar 2, 2026
- Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsYahoo Finance·Mar 2, 2026
- Dyne Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 25, 2026
- Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific ConferenceYahoo Finance·Feb 22, 2026
- Bullish Analyst Opinion on Dyne (DYNE) Follows Rare Disease Drug Progress in JapanYahoo Finance·Feb 19, 2026
- Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese MinistryYahoo Finance·Feb 16, 2026
- How Does Japan’s Orphan Nod Shape Dyne Therapeutics’ (DYN) Global Rare-Disease Strategy?Yahoo Finance·Jan 23, 2026
All 20 articles loaded
Price Data
Open$17.75
Previous Close$17.47
Day High$18.99
Day Low$17.56
52 Week High$25.00
52 Week Low$8.06
52-Week Range
$8.06$25.00
$18.84
Fundamentals
Market Cap$2.9B
P/E Ratio—
EPS$-3.47
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume1.7M
Avg Volume (10D)—
Shares Outstanding165.2M
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The company is headquartered in Waltham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—